Beilu Pharma(SZ:300016) Xin Lang Zheng Quan·2025-11-12 02:03Group 1 - The core viewpoint of the news is that Beilu Pharmaceutical has shown a significant increase in stock price and positive financial performance indicators, indicating potential growth and investor interest [1][2]. Group 2 - As of November 12, Beilu Pharmaceutical's stock price increased by 2.05% to 8.97 CNY per share, with a total market capitalization of 5.049 billion CNY [1]. - The company has experienced a year-to-date stock price increase of 45.85%, with a recent 5-day increase of 2.99% and a 20-day increase of 2.28%, although it has seen a decline of 8.38% over the past 60 days [1]. - Beilu Pharmaceutical's main business segments include contrast agents (63.33% of revenue), traditional Chinese medicine (22.09%), and diabetes medications (12.75%) [1]. Group 3 - For the period from January to September 2025, Beilu Pharmaceutical achieved operating revenue of 873 million CNY, representing a year-on-year growth of 19.59%, and a net profit attributable to shareholders of 44.177 million CNY, reflecting an 81.10% increase [2]. - The company has distributed a total of 369 million CNY in dividends since its A-share listing, with 59.03 million CNY distributed over the past three years [3].